IRWD at a glance
IRONWOOD PHARMACEUTICALS INC (IRWD, SEC CIK 1446847) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), IRONWOOD PHARMACEUTICALS INC (IRWD) reported revenue of $296.2 million (down 15.7% from FY2024) and net income of $24.0 million. Diluted EPS was $0.15.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding IRONWOOD PHARMACEUTICALS INC (IRWD) shares worth $346.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Silver Ronald on July 7, 2026 of 127,890 shares at $4.52 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $296.2M
- −15.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $346.3M · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $113.0M, up $27.8M YoY, driven by $24.4M higher U.S. LINZESS net profits
- Operating margin 70.2% vs 53.2% YoY, with operating income $79.3M vs $45.3M
- LINZESS best-performing product, generating $24.4M incremental U.S. net profits
- Apraglutide R&D increased to $18.8M from $17.0M YoY; IW-3300 R&D included a $(0.1)M credit
- STARS-2 initiated in June 2026; management cites regulatory uncertainty and continued substantial R&D investment as headwinds
Risk Factors
- New legal risk: Alkem Paragraph IV certification received June 12, 2026, challenging LINZESS patents
- Most material update: July 2026 New Jersey lawsuit triggered FDA approval stay through December 12, 2028
- Regulatory risk: USPTO IPR or PGR proceedings could invalidate or narrow LINZESS patent protection
- Operational risk: At-risk generic launch could significantly reduce LINZESS revenue within a short period
- Financial risk: LINZESS revenue concentration exposed to rapid erosion following patent-protection loss
AI summary of the IRWD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- No substantive Item 2.02 earnings information provided
- Investors should review the referenced earnings release for fiscal-year 2026 results
Item EX-99.1: Item EX-99.1
- Raised 2026 guidance: LINZESS U.S. sales $1.15–$1.20B, revenue $460–$485M, adjusted EBITDA above $310M
- Q2 LINZESS sales $282.3M, up 14%, supported by 4% demand growth and improved net pricing
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Ironwood held its 2026 Annual Meeting on June 16, 2026
- Section excerpt ends before disclosing director elections, officer departures, or compensation changes
Item 5.07: Submission of Matters to a Vote of Security Holders
- All eight director nominees elected to one-year terms through the 2027 Annual Meeting
- Alexander Denner received the lowest support, with 104,323,731 votes for and 5,313,973 withheld
Item 8.01: Other Events
- $200.0 million 1.50% convertible notes repaid at scheduled maturity on June 15, 2026
- Repayment funded entirely with available cash, reducing debt but lowering cash reserves
AI summaries of IRWD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IRWD
Don't miss the next IRWD filing
- Alerts as it files. A push when IRWD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IRWD, by share count.
- Ask anything. An AI agent that reads every IRWD filing and answers with sources.
IRWD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DENNER ALEXANDER J | A | Sep 15, 2026 | 3,694 | - |
| Silber Jeffrey | A | Jul 20, 2026 | 137,036 | - |
| Silver Ronald | Sell | Jul 7, 2026 | 127,890 | $4.52 |
| Moukheibir Catherine | A | Jun 16, 2026 | 63,481 | - |
| McHugh Julie | A | Jun 16, 2026 | 63,481 | - |
| McHugh Julie | Sell | Jun 16, 2026 | 21,571 | $3.73 |
| Shepard Jay | A | Jun 16, 2026 | 63,481 | - |
| DENNER ALEXANDER J | A | Jun 16, 2026 | 63,481 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $351.4M | $296.2M |
| Operating Income | - | $93.1M | $98.5M |
| Net Income | -$1.0B | $880K | $24.0M |
| Op. Margin | - | 26.5% | 33.3% |
| Net Margin | - | 0.3% | 8.1% |
| Balance Sheet | |||
| Total Assets | $471.1M | $350.9M | $396.9M |
| Equity | - | -$301.3M | -$261.8M |
| ROE | - | -0.3% | -9.2% |
| Per Share | |||
| EPS | $-6.45 | $0.01 | $0.15 |
| Cash Flow | |||
| Operating CF | - | $103.5M | $127.0M |
| CapEx | $273K | $142K | $34K |
Source: XBRL data in IRONWOOD PHARMACEUTICALS INC (IRWD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate IRWD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $346.3M |
| Q1 2026 | 28 | $265.4M |
| Q4 2025 | 24 | $230.4M |
| Q3 2025 | 26 | $86.0M |
| Q2 2025 | 27 | $42.7M |
| Q1 2025 | 25 | $73.8M |
| Q4 2024 | 22 | $206.6M |
| Q3 2024 | 19 | $111.1M |
- BlackRock+4.43M (+33%)
- State Street Corp+1.35M (+18%)
- Wells Fargo & Co+1.15M (+1950%)
- Morgan Stanley+1.04M (+125%)
- Goldman Sachs Group+623.2K (+23%)
- Two Sigma Investments−1.29M (-22%)
- Vanguard Portfolio Management LLC−1.17M (-17%)
- AQR Capital Management−1.07M (-14%)
- Invesco Ltd−144.2K (-26%)
- Renaissance Technologies LLC−67.8K (-1%)
- Truist Financial+35.5K
- Millennium Management−457.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 199 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IRWD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 17, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 8-K | May 21, 2026 | - | Analysis | |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
| 4 | Mar 12, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
IRWD SEC filings: frequently asked questions
Which institutions hold IRWD stock?
As of June 30, 2026, the largest IRONWOOD PHARMACEUTICALS INC (IRWD) holders among the 13F filers tracked by SignalX were BlackRock ($74.9 million), State Street Corp ($37.1 million), Bank of America Corp ($36.6 million), Renaissance Technologies LLC ($33.7 million), Vanguard Capital Management LLC ($27.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was IRWD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), IRONWOOD PHARMACEUTICALS INC (IRWD) reported revenue of $296.2 million (down 15.7% from FY2024) and net income of $24.0 million. Diluted EPS was $0.15. The figures come from the XBRL data in the 10-K.
What did IRWD report in its latest 8-K?
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). No substantive Item 2.02 earnings information provided.
What are the latest IRWD SEC filings?
IRONWOOD PHARMACEUTICALS INC (IRWD) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on September 17, 2026.
What is IRWD's SEC CIK number?
IRONWOOD PHARMACEUTICALS INC (IRWD)'s SEC Central Index Key (CIK) is 1446847. EDGAR lists every IRWD filing under that number.
Ask anything about IRWD
The research agent reads IRWD's filings, financials, insider trades and 13F holders, then answers with sources.